SEC Comment Letter 0000000000-24-010377 to Cuprina Holdings (Cayman) LTD (CUPR)
Cuprina Holdings (Cayman) LTD
Date: Sept. 13, 2024 · CIK: 0001995704 · Accession: 0000000000-24-010377
AI Filing Summary & Sentiment
File numbers found in text: 333-277731
Letter
September 13, 2024 David Quek Yong Qi Chief Executive Officer Cuprina Holdings (Cayman) Limited Blk 1090 Lower Delta Road #06-08 Singapore 169201 Re:Cuprina Holdings (Cayman) Limited Amendment No. 6 to Registration Statement on Form F-1 Filed September 9, 2024 File No. 333-277731 Dear David Quek Yong Qi: We have reviewed your amended registration statement and have the following comments. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Amendment No. 6 to Registration Statement on Form F-1 Prospectus Summary Corporate History and Structure, page 7 1.Please revise the chart in this section and on page 53 to show the post-offering ownership percentages. Business Licenses, Permits, Registrations and Approvals, page 103 2.Your disclosure on page 104 indicates that your Hong Kong import permit has expired. Please revise to clarify the status of this permit. Underwriting, page 160 We note your disclosure that the underwriters will offer selected dealers shares at the initial public offering price less a selling concession not in excess of US$4.50 per share. 3.
September 13, 2024 Page 2 We further note that the offering price per share to the public is between US$4.00 and US$4.50 per share. Please revise your disclosure or advise. General 4.Please revise the legal opinion filed as Exhibit 5.1 to quantify the number of shares and warrants being registered. Please contact Christine Torney at 202-551-3652 or Angela Connell at 202-551-3426 if you have questions regarding comments on the financial statements and related matters. Please contact Doris Stacey Gama at 202-551-3188 or Alan Campbell at 202-551-4224 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Lawrence Venick, Esq.
Show Raw Text
September 13, 2024
David Quek Yong Qi
Chief Executive Officer
Cuprina Holdings (Cayman) Limited
Blk 1090 Lower Delta Road #06-08
Singapore 169201
Re:Cuprina Holdings (Cayman) Limited
Amendment No. 6 to Registration Statement on Form F-1
Filed September 9, 2024
File No. 333-277731
Dear David Quek Yong Qi:
We have reviewed your amended registration statement and have the following
comments.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe a comment applies to your facts and circumstances
or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments.
Amendment No. 6 to Registration Statement on Form F-1
Prospectus Summary
Corporate History and Structure, page 7
1.Please revise the chart in this section and on page 53 to show the post-offering ownership
percentages.
Business
Licenses, Permits, Registrations and Approvals, page 103
2.Your disclosure on page 104 indicates that your Hong Kong import permit has expired.
Please revise to clarify the status of this permit.
Underwriting, page 160
We note your disclosure that the underwriters will offer selected dealers shares at the
initial public offering price less a selling concession not in excess of US$4.50 per share. 3.
September 13, 2024
Page 2
We further note that the offering price per share to the public is between US$4.00 and
US$4.50 per share. Please revise your disclosure or advise.
General
4.Please revise the legal opinion filed as Exhibit 5.1 to quantify the number of shares and
warrants being registered.
Please contact Christine Torney at 202-551-3652 or Angela Connell at 202-551-3426 if
you have questions regarding comments on the financial statements and related matters. Please
contact Doris Stacey Gama at 202-551-3188 or Alan Campbell at 202-551-4224 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Lawrence Venick, Esq.